|
|||||
|
|
Immune‐Related Adverse Events as a Biomarker in Non‐Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors |
|
| Authors: | Julia Judd Matthew Zibelman Elizabeth Handorf John O'Neill Chethan Ramamurthy Sasini Bentota Jamie Doyle Robert G. Uzzo Jessica Bauman Hossein Borghaei Elizabeth R. Plimack Ranee Mehra Daniel M. Geynisman |
| Affiliation: | 1. Department of Internal Medicine, Temple University Hospital, Philadelphia, Pennsylvania, USA;2. Departments of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA;3. Departments Biostatistics and Bioinformatics, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA;4. Department Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA |
| Abstract: | |
| Keywords: | Programmed cell death 1 inhibitors Nivolumab Pembrolizumab Checkpoint inhibitors Immunotherapy Immune‐related adverse events |